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The outcome for patients with relapsed Ewing’s sarcoma is poor. A retrospective analysis was carried out to identify factors asso-
ciated with improved survival. Between 1992 and 2002, 114 patients presented with relapsed or progressive disease. Median time
to progression/relapse was 13 months (range, 2–128). Treatment at relapse included high dose treatment (HDT) in 29 patients,
and surgery or deﬁnitive radiotherapy in 29. 2 and 5-year post relapse survival (PRS) was 23.5% and 15.2%, respectively. In multi-
variate analysis, the most signiﬁcant factors associated with improved survival were disease conﬁned locally or to the lungs (2-year
PRS, 40% versus 6%; P<. 001), relapse > 18 months from diagnosis (2-year PRS, 53% versus 8%; P<. 001), HDT at relapse
(2-year PRS, 62% versus 11%; P<. 001), and surgery and/or radiotherapy at relapse (2-year PRS, 51% versus 14%; P<. 001).
First treatment failure in Ewing’s sarcoma is mostly fatal. Improved survival can be achieved in selective patients with aggressive
treatment. These improvements are conﬁned to those without bone or bone marrow metastases.
Copyright © 2006 Anne M. McTiernan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Though still biologically enigmatic, Ewing’s sarcoma family
of tumours (ESFT) has now been repeatedly demonstrated
to be curable cancers. Results from large studies of ﬁrst-
linecombinedmodalitytreatmentsindicatethatperhapstwo
thirds of patients will be long-term survivors. However, for
patients with relapsed or progressive disease, the prognosis
is very poor, with only a small proportion of patients being
cured [1–3]. In order to identify the factors that might be as-
sociated with improved survival in patients with relapsed or
progressive ESFT, we carried out a retrospective analysis at
our institution, together with a review of the literature.
PATIENTS AND METHODS
Patientscharacteristics
Between 1992 and 2002, 61 males and 53 females, median
age 19 (range, 4–48), presented to the London Bone and
Soft Tissue Sarcoma Service with relapsed or progressive
ESFT. The patient characteristics are given in Table 1.F i f t y -
three patients had metastases at diagnosis, of whom 29 had
metastases conﬁned to the lungs. Primary site was of the ex-
tremities in 56 patients, pelvis in 30 patients, and central
(nonpelvic) in 26. Two other patients had multifocal tu-
mours. There were 87 primaries in bone and 27 soft-tissue
tumours. The median tumour volume, assessed in 86 pa-
tients, was 255mL (range, 50–3500mL). Diagnosis had been
established by morphology and immunocytochemistry in all
patients, with no routinic use of molecular diagnostic tech-
niques. Conﬁrmation of recurrence by biopsy was under-
taken whenever possible.
First-linetreatment
Details of ﬁrst-line chemotherapy are given in Table 1.T h e
majority of patients (90%) had been treated in accordance
with successive European protocols for ESFT, with those di-
agnosed before 1993 being treated according to the ET-2
protocol [4]; those diagnosed between 1993 and 1997 being
treated according to the Eicess’ 92 protocol [5]; and patients
diagnosed from 1998 onwards being treated with 6 cycles of
vincristine, ifosfamide, doxorubicin, and etoposide, followed
byconsolidationtreatmentwitheither8cyclesofvincristine,
actinomycin, and ifosfamide or cyclophosphamide, or high-
dose therapy (HDT) with busulphan and melphalan [6], in
accordance with the current EURO-EWING 99 protocol (IS-
RCTN:61438620). All but 3 patients received doxorubicin2 Sarcoma
Table 1: Patients characteristics. (Abbreviations: V = vincristine; D
= doxorubicin; I = ifosfamide, E = etoposide, A = actinomycin-D, C
= cyclophosphamide; HDT = high-dose therapy; PD= progressive
disease.)
No (%)
Median age at diagnosis: 19 years (range 4–48)
Male 61 (53.5)
Female 53 (46.5)
Site of primary:
Extremity 56 (49.2)
Axial/Central
Pelvis 30 (26.3)
Trunk 22 (19.4)
Other(a) 4( 3 .5)
Multifocal 2 (1.8)
Size of primary tumour:
< 100mL 73 (64.0)
> 100mL 13 (11.4)
Unknown 28 (24.6)
Metastases at diagnosis:
None 61 (53.5)
Lung only 29 (25.4)
Bone ± other, (excluding bone marrow) 8 (7.0)
Bone marrow ± other 14 (12.3)
Lymph node 2 (1.8)
First-line chemotherapy protocol:
ET-2 (VAID) 17 (14.9)
Eicess’ 92 (VAID ±E ±C) 50 (43.9)
EE99 (EVAID ±C ±HDT) 36 (31.2)
P6 (VDCIE) 5 (4.4)
MMT’89 (VAI or VAC) 3 (2.6)
VDC 2 (1.8)
ID 1 (< 1)
Site of ﬁrst relapse/PD:
Local 29 (25.4)
Distant
Lung only 32 (28.1)
Extrapulmonary 33 (28.9)
Combined
Local + lung only 8 (7.0)
Local + extrapulmonary 12 (10.5)
(a) Other: scalp = 1, sphenoid = 1, mandible = 1, neck = 1, multifocal = 2.
and all but 4 patients received ifosfamide as part of ﬁrst-line
treatment. Fourteen patients received HDT as consolidation
of ﬁrst-line therapy.
Localtreatment
Local treatment was surgery alone in 34 patients, surgery
and adjuvant radiotherapy in 20 patients (2 patients with
preoperative radiotherapy), and radiotherapy alone in 46
patients. Fourteen patients had no local treatment due to
widespreadbonemetastasesin3patients(all3receivedHDT
as part of ﬁrst-line treatment), disease progression in 8 pa-
tients, persistent bone marrow disease in 2, and patient re-
fusal in the presence of widespread metastatic disease in 1.
One further patient underwent pulmonary metastatectomy
for persistent pulmonary metastases at the end of ﬁrst-line
treatment.
Statisticalmethods
Survival after ﬁrst treatment failure, termed postrelapse sur-
vival(PRS),wascalculatedfromthedateofPDorrecurrence
to the date of death or date of last followup. The duration
of ﬁrst event-free survival (EFS1) was calculated from the
date of diagnosis to the date of ﬁrst treatment failure. PRS
was estimated using Kaplan-Meier methods [7]. The signif-
icance of inﬂuencing factors was tested by the log-rank test.
In the case of more than two curves, the overall P value was
given. Factors considered included demographic factors (age
at diagnosis, gender, and age at relapse), diagnostic factors
(primary site, metastases at diagnosis, tumour volume), lo-
cal treatment in ﬁrst-line therapy, factors at relapse (timing
of relapse and site of relapse), and treatment at relapse. Mul-
tivariate analysis was carried out using Cox’s proportional
hazards model [8], with all variables found to be signiﬁcant
inunivariateanalysisbeingenteredintoamultivariatemodel
using a stepwise procedure.
RESULTS
Detailsatrelapse/progressivedisease
Thirty-seven patients developed PD within ﬁrst-line treat-
mentand77recurrentdisease.Themediantimetoﬁrsttreat-
mentfailurewas13months(range,2–128months)with42%
ofeventsoccurringwithintheﬁrst12months.Siteofﬁrstre-
lapse or progression is given in Table 1.
Treatmentofrelapse
Chemotherapy
Eighty-nine patients (78%) were treated with chemother-
apy at relapse, 12 with palliative intent only. Chemotherapy
details at relapse are given in Table 2.S e v e r a ld i ﬀerent reg-
imens were employed reﬂecting patient factors (major or-
gan function, duration of remission, need for mobilisation,
and collection of stem cells) and evolving practice. Patients
were often treated with more than one regimen in an at-
tempt to reduce disease burden to the minimum achiev-
able one. The majority of patients were treated with second-
line regimens, principally carboplatin-based chemotherapy
[9]. When short durations of response with carboplatin reg-
imens were observed, and in response to others’ data, high-
doseifosfamide,atamediandoseof15g/m2 (range12g/m2–
18g/m2), was employed [10]. Twenty-two patients, the ma-
jority of whom relapsed more than 6 months from theAnne M. McTiernan et al 3
Table 2: Deﬁnitive treatment at relapse. (Abbreviations: RT = ra-
diotherapy; HDT = high-dose therapy; TBI = total body irradia-
tion.)
Treatment No
Chemotherapy (n = 89)
– Carboplatin, etoposide, cyclophosphamide 26
– Ifosfamide, doxorubicin, +/− actinomycin,
+/− vincristine, +/− etoposide 22
– High-dose ifosfamide (12–18g/m2)1 8
–O t h e r (a) 11
– Palliative only 12
Surgery (n = 20)
– Excision of local recurrence (no RT) 11
– Excision of local recurrence + RT 4
– Metastatectomy: Lung 3
Cerebral 1
Para-spinal mass 1
Deﬁnitive radiotherapy (n = 8)
–L o c a lr e c u r r e n c e 4
–B o n em e t a s t a s e s 4
HDT (n = 29)
– Busulphan + melphalan 19
– Melphalan + etoposide (+ TBI, 3 patients) 7 (3)
– Melphalan (+ TBI, 1 patient) 2 (1)
– Busulphan + cyclophosphamide 1
(a) Other: ifosfamide + etoposide = 3; cisplatin + etoposide ± vincristine =
3; vincristine + doxorubicin + cyclophosphamide = 3; cyclophosphamide +
topotecan = 1; ifosfamide + vincristine = 1.
end of ﬁrst-line treatment, were initially retreated with an
ifosfamide/doxorubicin-based regimen, to maximise expo-
sure to anthracycline-based chemotherapy. Twenty-ﬁve pa-
tients were not treated with chemotherapy at relapse or pro-
gression, due to either poor tolerance in the presence of
widespread refractory disease or rapid relapse after HDT, or
patient choice.
Highdosetherapyatrelapse
Twenty-nine of 77 patients (38%) treated with curative
intent at progression/relapse were treated with high-dose
chemotherapyaftersecond-linechemotherapy.Patientswere
treated with second-line treatment until remission was
achieved or there was no further response. HDT comprised
of busulphan and melphalan in 19 patients, and other reg-
imens in 10. For those who proceeded to HDT at relapse,
the median time from diagnosis to relapse was 23 months
(range, 3–70 months). The best response at time of HDT
was CR in 13 patients, PR in 8, responding disease in 7, and
progressive disease in 1 patient. This latter patient had op-
erable lung metastases at relapse and was therefore deemed
suitable for HDT, despite disease progression. All other pa-
tients treated with curative intent were initially considered
for HDT, but did not receive it principally due to inadequate
response to second-line chemotherapy, rapid progression of
initially responding disease, insuﬃcient major organ func-
tion, or patient preference. The probability of a patient re-
ceiving HDT at relapse remained constant over the 10-year
period (P = .589).
Surgery
Twenty-one patients (18%) had surgery as part of second-
line treatment, although for one patient this was for pallia-
tive amputation of local recurrence only. Fifteen underwent
excision of a local recurrence (4 with adjuvant radiother-
apy), achieving second complete remission in 11 patients,
and 4 with disease elsewhere, in anticipation of proceeding
to HDT. Metastatectomies were performed in 5 patients, all
with complete macroscopic excision. Three patients under-
went lung metastatectomy (one with adjuvant whole lung ir-
radiation), 1 patient had a cerebral metastatectomy, and 1
patient underwent excision of a para-spinal mass. In total,
complete macroscopic resections were achieved in 16 of the
20 patients.
Radiotherapy
Sole deﬁnitive radiotherapy for relapse was given to 8 pa-
tients. In 4 patients this was for local recurrence deemed
unresectable (3 extremity tumours, 1 chest wall). Three pa-
tients, 1 of whom also underwent HDT, received deﬁnitive
radiotherapy to isolated bone metastases, and 1 patient with
2 sites of distant metastases received radiotherapy to both
sites following TBI (given as part of HDT) to achieve a radi-
cal dosage to both sites of disease.
Survival
Postrelapsesurvival
At 1st April 2005, the median followup for the whole group
was 67 months (range, 0–129). At this time 14 patients
(12.3%) remained alive continuously disease free, with a me-
dian followup of 61 months from ﬁrst relapse (range, 35–129
months). Another patient was alive and disease free follow-
ingresectionofafurtherloco-regionalrecurrence58months
after ﬁrst relapse, and a second patient had become lost to
followup with uncontrolled disease 19 months from relapse.
Three patients (2.6 % )d i e do fc a u s e sr e l a t e dt of u r -
ther treatment. One died of pneumocystis carinii during
chemotherapy for a second relapse having previously been
treated with HDT; one patient died of gastrointestinal toxi-
city 3 months after HDT; and one patient suﬀered radiation
pneumonitis with lung abscesses and chronic infection after
HDT and lung irradiation, dying 18 months later. Recurrent
disease was suspected but not proven to be present.
T h em e d i a ne s t i m a t e dP R Sf o rt h ew h o l eg r o u pw a s9
months (range 0–129), with the 2- and 5-year estimated PRS
being 23.5% (±4.0%, standard error) and 15.2% (±3.4%),
respectively (Figure 1).4 Sarcoma
Table 3: Summary of univariate analysis. (Abbreviations: SE = standard error; EFS1 = ﬁrst event free survival; NR = not reached; RT =
radiotherapy.)
Variable Grouping No of patients % Postrelapse survival (±1S E ) P value
2-year 5-year (log rank)
All patients — 114 23.5( ±4.0) 15.2( ±3.4) —
Demographics
Gender Male 61 19.7( ±5.1) 14.8( ±4.6) .9902
Female 53 28.0( ±6.2) 15.7( ±5.1)
Age at diagnosis
≤ 19 years 62 22.1( ±5.3) 15.1( ±4.7) .8042
≥ 20 years 52 25.0( ±6.0) 15.4( ±5.0)
Disease at diagnosis
Primary site
Extremity 56 30.1( ±6.2) 20.4( ±5.5)
.5163∗ Pelvis 30 20.0( ±7.3) 13.3( ±6.2)
Central 26 15.4( ±7.1) 7.7( ±5.2)
Multifocal 2 0—
Metastases
None 61 32.4( ±6.0) 18.8( ±5.1)
<. 0001 Lung 29 24.1( ±8.0) 20.1( ±7.6)
Extra-pulmonary 24 0—
Relapse details
Relapse type
Local relapse 29 37.9( ±9.0) 34.5( ±8.8)
.0189 Distant relapse 65 20.0( ±5.0) 9.2( ±3.6)
Combined 20 13.3( ±8.1) NR
Relapse site
Local only 29 37.9( ±9.0) 34.5( ±8.8)
<. 0001 Lung ± local 40 32.1( ±7.4) 15.3( ±6.0)
Extra-pulmonary 45 6.7( ±3.7) 2.2( ±2.2)
EFS1 < 18 months 75 8.0( ±3.1) 6.7( ±2.9) <. 0001
≥ 18 months 39 53.4( ±8.1) 31.6( ±7.6)
Worst extent of disease
Local 20 40.0( ±11.0) 35.0( ±10.7)
<. 0001 Lung 40 39.7( ±7.8) 23.3( ±6.9)
Extra-pulmonary 54 5.6( ±3.1) 1.9( ±1.8)
Relapse treatment
Chemotherapy or HDT
HDT 29 61.7( ±9.1) 50.6( ±9.5)
<. 0001 Chemotherapy 48 16.7( ±5.4) 4.2( ±2.9)
None/palliative 37 2.7( ±2.7) NR
Surgery and/or RT Yes 29 51.1( ±9.4) 39.6( ±9.3) <. 0001
No 85 14.1( ±3.8) 7.1( ±2.8)
∗2 patients with multifocal tumours are excluded from this comparison.
Factorsinﬂuencingsurvival
Table 3 lists the PRS according to age, gender, primary site,
metastases at diagnosis, relapse details, and treatment at re-
lapse.
Factorsatdiagnosis
No inﬂuence on PRS was evident for gender, age at diagno-
sis, age at relapse, primary site, or tumour volume (Table 3).
When grouped together, patients with metastases at diag-
nosis had a poorer PRS compared to those with no metas-
tases, but this was largely accounted for by the poor survival
of 24 patients with extra-pulmonary metastases at diagnosis
(Table 3).
Factorsatrelapse
Patients with local recurrence or lung metastases at relapse
(with or without local recurrence) had superior survivalAnne M. McTiernan et al 5
Table 4: Summary of multivariate analysis.
Variable1
Postrelapse survival
Parameter estimate P (chi-sq) Hazard ratio 95% CI
EFS1 ≥ 18 months −1.007 < 0.001 0.365 0.22–0.59
Disease conﬁned to local/lung at both
diagnosis and relapse
−1.085 < 0.001 0.338 0.22–0.52
Surgery and/or radical RT to site of
recurrence
−0.657 0.019 0.518 0.20–0.90
HDT −1.164 < 0.001 0.312 0.17–0.58
1Reference: relapse within 18 months, extra-pulmonary disease at diagnosis and/or relapse, no deﬁnitive local therapy at relapse, no HDT at relapse.
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Figure 1: Postrelapse survival according to all patients (n = 114).
compared to those with extra-pulmonary recurrence. More-
over, patients with disease conﬁned locally or to the lungs
at both diagnosis and relapse had superior survival to those
with extra-pulmonary disease at any time. Relapse within
the ﬁrst 18 months was also associated with inferior survival
(Table 3).
Treatmentatrelapse
Whether patients received HDT or not at relapse was the
strongest predictor of survival in univariate analysis, with a
5-year PRS of 50.6% (±9.5%) for those who received HDT
compared to 3.5% (±2.0%) for those who did not (P<. 001;
Figure 2). The ability to perform deﬁnitive local treatment
to the site of relapse was also a strong predictor of outcome,
with no diﬀerence seen between those who received surgery
or those who received radiotherapy (Table 3).
Multivariateanalysis
When considered in multivariate analysis, the strongest fac-
tors associated with superior survival were disease conﬁned
either to the primary site or to the lungs at both diagnosis
and relapse; relapse greater than 18 months from diagnosis;
144 132 120 108 96 84 72 60 48 36 24 12 0
Survival post relapse (months)
0
0.2
0.4
0.6
0.8
1
C
u
m
s
u
r
v
i
v
a
l
No (n = 85)
Yes (n = 29)
Figure 2: Postrelapse survival according to high-dose therapy
(HDT) at relapse (P<. 001).
HDT at relapse; and deﬁnitive treatment to the site of relapse
(Table 4).
DISCUSSION
This report describes the outcome of a large series of patients
with ESFT after failure of ﬁrst-line treatment. Although this
is a retrospective analysis, the data presented is especially
valuable as it reﬂects relatively recent practice in this dis-
ease, as this large number of patients has all been treated
withina10-yearperiod.Althoughtheoutcomeforthegroup
overall is poor, there are a notable number of long-term sur-
vivors, and important and consistent factors associated with
improved survival have been identiﬁed.
The 5-year PRS survival of 15.2% in this group of pa-
tients is in accordance with that described elsewhere. Re-
ports detailing studies of ﬁrst-line treatment describe a PRS
b e t w e e n0a n d2 2 %[ 11–18], although many of these stud-
ies includeonly patients with localised disease at diagnosis6 Sarcoma
Table 5: Outcome of patients with relapsed Ewing’s tumours, derived from reports of prospective clinical trials of ﬁrst-line therapy. (Abbre-
viations: AAW = alive and well; AWD = alive with disease; DR = distant recurrence; FU = followup; LR = local recurrence; PRS = postrelapse
survival; PR = postrelapse.)
Study,
Patients at
diagnosis
Median FU
years (range)
Relapsed
patients
Outcome after
relapse Notes period of study,
author
150
Overall:
8 AAW; 6 AWD — 359 10.5L R = 1
Localised (3.5–19) DR = 108
Bacci et al [11]
1979–1995
Both(a) = 41
142 88
Only 2 of 76 with
metastatic relapse AAW — 120 localised 11.2L R = 26
22 metastatic (4.7–12) DR = 52
ET-1
1978–1986
Craft et al [12]
Both = 10
125 5-year PRS –R e l a p s e> 2 years prognosis
(P = .0015) better 5 year PRS:
18% versus 10%
– Type of relapse not signiﬁcant
(P = .3095)
407 6.4L R = 22 LR: 22% (4–41%)
localised (0.2–13) DR = 92 DR: 11% (4–17%)
CESS 86
1986–1991
Paulussen et al [13]
Both = 11 Both: 9% (0–26%)
54 27
All died — localised 31 6.8L R = 4
metastatic 23 (min3) DR = 17
NCI-86C169
1986–1992
Wexler et al [14]
Both = 6
61
11 alive(b)
–R e l a p s e> 2 years better
prognosis (P = .001)
– Relapse site: not
signiﬁcant (P = .1)
191 5.5L R = 10
Localised (0.2–10) DR = 43
ET2
1987–1993
Shankar et al [15]
Both = 8
43
42 died: 6–128 months
P R1A A W ,1 2y e a r sP R — 77 11 LR = 6
Local-pelvis (5–23) DR = 24
Bacci et al [16]
1979–1996
Both = 13
(a)Deﬁned by these authors as any patient who has ever experienced both a local recurrence and distant recurrence, regardless of the interval between them.
(b)Disease status is not given.
(Table 5). Time to ﬁrst relapse has commonly been found to
be a signiﬁcant factor in inﬂuencing PRS, with those who
relapse within 2 years of diagnosis having an inferior sur-
vival compared to those who relapse beyond 2 years [1–
3, 15, 17, 19, 20]. In this study we found that a cutoﬀ of
18 months was a stronger predictor of survival, those re-
lapsing after 18 months having an estimated 5-year PRS of
32%.Whendiseaseprogressionoccursduringﬁrst-linetreat-
ment subsequent survival is rarely reported. However 3 of 37
patients described in this study are long-term survivors, in-
dicating that long-term remissions can occasionally be ob-
tained with intensive treatments in selected patients with
early progression.
Only a small number of studies have speciﬁcally exam-
ined survival after relapse in ESFT (Table 6). From these
studies, factors associated with superior survival included
relapse (rather than progression within ﬁrst-line treatment)
[21]; local recurrence only [1]; lung metastases rather than
extra-pulmonary disease [1, 3]; deﬁnitive surgery and/or ra-
diotherapy to the site of relapse [1, 3]; response to second-
line therapy [22]; HDT at relapse [22]; and relapse more
than 2 years from diagnosis [1–3, 20, 22]. Where stated, 5-
year PRS from these studies ranged from 13.8% to 20.0%,
(Table 6).
The survival of the cohort reported here compares
favourably with these series, as the analysis was not conﬁned
to those with just localised disease at diagnosis and all had
been treated with modern ﬁrst-line regimens. A key goal in
analysing and reporting this series was to identify treatment
factorsthatmightimprovesurvivalafterrelapseofESFT.The
results indicate the importance of an aggressive approach to
local failure and, in particular, suggest a role for HDT inAnne M. McTiernan et al 7
Table 6: Speciﬁc studies on the outcome of patients with relapsed Ewing’s tumours. (Abbreviations: CHRMC = Children’s Hospital and
Regional Medical Center; AAW = alive and well; AWD = alive with disease; DR = distant recurrence; FLT = ﬁrst-line treatment; FU =
followup; LR = local recurrence; NS = not speciﬁed; Post Tr = posttreatment; PRS = postrelapse survival; LBSTS = London Bone and Soft
Tissue Service; 2LT = second- line treatment.)
Study,
Patients at
diagnosis
Median FU
years (range)
Relapsed
patients
Outcome after
relapse
Factors associated with
improved outcome period of study,
author
St Judes 78
NS
56
1964–1980(a)
localised 22 in FLT → All died
→ 16 AAW, 2 AWD
-NS
Hayes et al [21] 34 Post Tr.
Eicess Database
272
7 104
89 died –R e l a p s e> 2 years
(10-year PRS:
0% versus 33%)
1981–1990
localised 10-year PRS: 10% Paulessen et al [20]
(Abstract)
(Relapsed only)
NS
71 5-year PRS: (overall 17.7%) –R e l a p s e> 2 years
– LR only
– Surgery for LR
–D R= lung only
– Lung irradiation
41 localised
LR = 25 LR: 22% (±8%, SE)
30 metastasic
DR = 34 DR: 18% (±7%)
Both = 12 Both 13% (±8%)
St Judes
1979–1999
Rodriguez-
Galindo
et al [1]
191
NS
64 Overall:
3 AAW; 4 AWD
55 died(b)
2 lost to FU
–R e l a p s e> 2
years localised
LR = 11
DR = 42
ET-2
1985–1996
Shankar et al [2]
Both = 11
429
NS
195
5-year PRS:1 3 .8%
–R e l a p s e> 2 years
–S u r g e r yo rR Ta t
relapse
–D R= lung only
localised
LR = 1
DR = 138
Rizzoli
1979–1997
Bacci et al [3]
Both(c) = 56
(Relapsed only)
NS
55 5-year PRS: (overall 20%)
–R e l a p s e> 2 years
–R e s p o n s et o2 L T
– HDT at relapse
30 localised LR = 6 LR: 50% (95% CI, 9–91)
25 metastasic DR = 39 DR: 20% (95% CI, 7–33)
CHRMC, Seattle
1985–2002
Barker et al [22]
Both = 10 Both: 0
LBSTS (this report)
(Relapsed only) 114 5-year PRS: (overall 15.2%) –R e l a p s e> 18 months
– Local or lung disease only
– Surgery or RT at relapse
– HDT at relapse
1992–2002
61 localised 5.6L R = 29 LR: 35% (±9%)
53 metastatic (1.1–10.8) DR = 65 DR: 9% (±4%)
Both = 20 Both: 0%
(a)Includes 3 patients who had no chemotherapy during ﬁrst-line treatment.
(b)1 patient died in a road traﬃc accident, apparently disease free.
(c)Deﬁned by these authors as any patient who has ever experienced both a local recurrence and distant recurrence, regardless of the interval between them.
improving PRS, previous evidence for which has principally
been derived from registry reports [23, 24].
In this study, beneﬁt of intensive treatment was conﬁned
to those with either local disease or lung metastases. It is
therefore possible that a beneﬁt similar to that reported for
HDT might have been achieved had lung irradiation been
used instead. This however seems unlikely as other evidence
indicates only a small eﬀect from the use of lung irradiation
[25] and also when second-line treatment for ESFT fails, dis-
ease rarely remains conﬁned to the lungs.
A limitation of all these studies is that as retrospective
analyses it is not possible to control for selection bias. In
both this series and that conducted by Barker et al [22], it
is probable that some of the long-term survivors may have
achieved the same status without the use of HDT. However
it is unlikely that this would be the case for all the survivors
in the series reported here. In the absence of evidence from
prospective randomised studies of HDT in patients with re-
lapsed ESFT, which would present insuperable challenges to
conduct, consolidation of response with HDT would appear8 Sarcoma
to be an appropriate goal where possible, given the otherwise
uniformly dismal outlook for patients with relapsed disease.
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